You just read:

Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint

News provided by

Tolerx, Inc.

Mar 11, 2011, 09:02 EST